首页> 外文期刊>Journal of applied microbiology >Beneficial activity of Enterococcus faecalis CECT7121 in the anti-lymphoma protective response.
【24h】

Beneficial activity of Enterococcus faecalis CECT7121 in the anti-lymphoma protective response.

机译:粪肠球菌CECT7121在抗淋巴瘤保护反应中的有益活性。

获取原文
获取原文并翻译 | 示例
       

摘要

Aims. To study the anti-tumour effects of Enterococcus faecalis CECT7121 on LBC cells, an aggressive murine T-cell lymphoma that kills the host in 18 days when is intraperitoneally (i.p.) administrated. Methods and Results. In vitro studies have shown that LBC cell proliferation was inhibited by Ent. faecalis CECT7121 stimulus in a dose-dependent manner, inducing apoptosis. The production of ceramide was involved in the latter effect. To undertake in vivo studies, syngeneic BALB/c mice pre-treated i.p. with Ent. faecalis CECT7121 (2.5 x 108 CFU) were challenged i.p. with LBC cells (1.0 x 106 cells) the day after. On day 30 post-inoculation of LBC cells, 70% of Ent. faecalis CECT7121 pre-treated mice survived, whereas no survivals were recorded in the control group. A group of surviving mice was re-challenged with LBC cells, and 89% of them survived. Upon stimulation with irradiated LBC cells, spleen cell proliferation, high IFN gamma, IL-12 and IL-10 levels were observed in surviving animals. Conclusions. Enterococcus faecalis CECT7121 affected multiple factors of the tumour establishment by the following methods: down-regulating the LBC cell proliferation and inducing apoptosis in these cells; and enhancing the immune response that protects animals from lymphoma challenge and re-challenge. Significance and Impact of the Study. This study demonstrate that Ent. faecalis CECT7121 has potential as a probiotic that could facilitate the development of novel complements to therapeutic strategies against oncological diseases
机译:目的为了研究粪肠球菌CECT7121对LBC细胞的抗肿瘤作用,一种腹膜内(i.p.)施用的侵袭性鼠T细胞淋巴瘤可在18天之内杀死宿主。方法和结果。体外研究表明,Ent抑制LBC细胞增殖。粪便CECT7121以剂量依赖性方式刺激,诱导细胞凋亡。神经酰胺的产生与后者的作用有关。为了进行体内研究,同系BALB / c小鼠经腹腔内预处理。与Ent。粪便CECT7121(2.5 x 108 CFU)腹腔注射次日使用LBC细胞(1.0 x 106细胞)。接种LBC细胞后第30天,Ent的70%。粪便CECT7121预处理的小鼠存活,而对照组没有存活。一组存活的小鼠再次受到LBC细胞的攻击,其中89%存活。在用照射的LBC细胞刺激后,在存活的动物中观察到脾细胞增殖,高IFNγ,IL-12和IL-10水平。结论。粪肠球菌CECT7121通过以下方法影响肿瘤形成的多个因素:下调LBC细胞增殖并诱导这些细胞凋亡。并增强保护动物免受淋巴瘤攻击和再攻击的免疫反应。研究的意义和影响。这项研究证明了恩特。粪便CECT7121具有作为益生菌的潜力,可以促进针对肿瘤疾病治疗策略的新型补体的开发

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号